Cidara Therapeutics Achieves Enrollment Goal for Phase 3 ANCHOR Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Trial Enrollment: Cidara Therapeutics has completed target enrollment of 6,000 participants for its Phase 3 ANCHOR trial in the US and UK, focusing on high-risk populations for seasonal influenza complications.
CD388 Evaluation: The trial assesses the safety and efficacy of CD388, a non-vaccine preventative for influenza, administered as a one-time 450-milligram subcutaneous dose to adults and adolescents.
Interim Analysis: An interim analysis is scheduled for the first quarter of 2026 to evaluate trial size and determine if additional enrollment is needed during the Southern Hemisphere flu season.
Regulatory Potential: If successful, results from this Phase 3 trial may support a Biologics License Application (BLA) approval for CD388 in the high-risk populations studied.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on CDTX
Wall Street analysts forecast CDTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 209.67 USD with a low forecast of 173.00 USD and a high forecast of 221.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
2 Buy
6 Hold
0 Sell
Hold
Current: 221.380
Low
173.00
Averages
209.67
High
221.50
Current: 221.380
Low
173.00
Averages
209.67
High
221.50
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck in Talks to Acquire Revolution Medicines for $28-32 Billion
- Acquisition Talks: Merck is reportedly in discussions to acquire Revolution Medicines for a deal valued between $28 billion and $32 billion, which, if finalized, would mark the largest transaction in the biotech sector, further fueling the ongoing M&A boom.
- Stock Reaction: Following the news, Revolution Medicines' shares surged by 15.14%, now trading at $123.65 per share, indicating strong market optimism regarding the potential deal and possibly enhancing the company's position in cancer treatment.
- Industry Context: This acquisition discussion comes amid a looming patent cliff for the biotech industry, with Merck's Keytruda set to lose patent protection in 2028, making this acquisition crucial for diversifying its product portfolio to address future challenges.
- M&A Trends: According to S&P Capital IQ, biotech deal volumes are projected to reach $135 billion by 2025, doubling from 2024, highlighting an acceleration in M&A activity, with Merck's potential acquisition likely to further drive this trend.
Continue Reading
HighVista Initiates Position in Cidara with 70,904 Shares Worth $6.79 Million
- New Investment Position: HighVista Strategies initiated a position in Cidara Therapeutics by acquiring 70,904 shares valued at $6.79 million during Q3 2025, representing 1.66% of its 13F reportable assets, indicating a strategic interest in the biotech sector.
- Outstanding Market Performance: As of November 13, 2025, Cidara's shares were priced at $105.99, reflecting a remarkable 662.52% increase over the past year, with a one-year alpha of 675.44 percentage points, showcasing strong market confidence in its future prospects.
- Acquisition News: Cidara recently announced its acquisition by Merck at a price of $221.50 per share, which is expected to keep its stock price elevated in the short term, reflecting market anticipation for its promising influenza prevention drug candidate, CD388.
- Strategic Implications: HighVista's investment comes at a pivotal moment, as Cidara's shareholders stand to benefit from potential drug sales following the Merck acquisition, while HighVista's new stake may yield significant returns in the future.
Continue Reading